Once-yearly zoledronic acid in hip fracture prevention

References

• RaiszLPathogenesis of osteoporosis: concepts, conflicts, and prospectsJ Clin Invest2005115123318332516322775
   PubMed Web of Science ®Google Scholar
• ClowesJEastellRThe role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture riskBaillieres Best Pract Res Clin Endocrinol Metab200014221323211035903
   PubMed Web of Science ®Google Scholar
• BurgeRDawson-HughesBSolomonDWongJKingATostesonAIncidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res200722346547517144789
   PubMed Web of Science ®Google Scholar
• SirisEMillerPBarrett-ConnorEIdentification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmeno-pausal Women. Results From the National Osteoporosis Risk AssessmentJAMA2001286222815282211735756
   PubMed Web of Science ®Google Scholar
• WilkinsCBirgeSPrevention of osteoporotic fractures in the elderlyAm J Med2005118111190119516271899
   PubMed Web of Science ®Google Scholar
• ReginsterJBurletNOsteoporosis: A still increasing prevalenceBone2006382 Suppl 1S4S916455317
   PubMed Web of Science ®Google Scholar
• ColeZDennisonECooperCOsteoporosis epidemiology updateCurr Rheumatol Rep2008102929618460262
   PubMedGoogle Scholar
• JohnellOKanisJEpidemiology of osteoporotic fracturesOsteoporos Int200516Suppl 2S3S715365697
   PubMed Web of Science ®Google Scholar
• CooperCAtkinsonEJacobsenSO’FallonWMeltonLrPopulation-based study of survival after osteoporotic fracturesAm J Epidemiol19931379100110058317445
   PubMed Web of Science ®Google Scholar
• FarahmandBMichaelssonKAhlbomALjunghallSBaronJSurvival after hip fractureOsteoporos Int2005161583159016217590
   PubMed Web of Science ®Google Scholar
• HaentjensPBoonenSExcess mortality after hip fracture among postmenopausal women and ageing men: evidence from data searches and life-table analyses for gender-related differences in absolute risk of death after hip fractureOsteporosis Int200718Suppl 1S5S6
   Google Scholar
• TorgersonDDolanPPrescribing by general practitioners after an osteoporotic fractureAnn Rheum Dis19985763783799771215
   PubMed Web of Science ®Google Scholar
• KamelHHussainMTariqSPerryHMorleyJFailure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fractureAm J Med2000109432632810996585
   PubMed Web of Science ®Google Scholar
• KamelHDuthieEThe underuse of therapy in the secondary prevention of hip fracturesDrugs Aging200219111011929323
   PubMed Web of Science ®Google Scholar
• AndradeSMajumdarSChanKLow frequency of treatment of osteoporosis among postmenopausal women following a fractureArch Intern Med2003163172052205714504118
   PubMed Web of Science ®Google Scholar
• SolomonDFinkelsteinJKatzJMogunHAvornJUnderuse of osteoporosis medications in elderly patients with fracturesAm J Med2003115539840014553876
   PubMed Web of Science ®Google Scholar
• Colón-EmericCLylesKHousePRandomized trial to improve fracture prevention in nursing home residentsAm J Med20071201088689217904460
   PubMed Web of Science ®Google Scholar
• KlotzbuecherCRossPLandsmanPAbbottTrBergerMPatients with prior fractures have an increased risk of future fractures:a summary of the literature and statistical synthesisJ Bone Miner Res200015472173910780864
   PubMed Web of Science ®Google Scholar
• KanisJJohnellOLaetCDA meta-analysis of previous fracture and subsequent fracture riskBone200435237538215268886
   PubMed Web of Science ®Google Scholar
• CenterJBliucDNguyenTEismanJRisk of subsequent fracture after low-trauma fracture in men and womenJAMA200729738739417244835
   PubMed Web of Science ®Google Scholar
• FriesendorffMVBesjakovJÅkessonKLong-term survival and fracture risk after hip fracture: a 22-year follow-up in womenJ Bone Miner Res200823111832184118597630
   PubMed Web of Science ®Google Scholar
• HamletWLiebermanJFreedmanEDoreyFFletcherAJohnsonEInfluence of health status and the timing of surgery on mortality in hip fracture patientsAm J Orthop19972696216279316725
   PubMedGoogle Scholar
• CenterJNguyenTSchneiderDSambrookPEismanJMortality after all major types of osteoporotic fracture in men and women: an observational studyLancet1999353915687888210093980
   PubMed Web of Science ®Google Scholar
• BhattacharyyaTIorioRHealyWRate of and risk factors for acute inpatient mortality after orthopaedic surgeryJ Bone Joint Surg Am200284-A456257211940616
   PubMed Web of Science ®Google Scholar
• MagazinerJFredmanLHawkesWChanges in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling agedAm J Epidemiol2003157111023103112777366
   PubMed Web of Science ®Google Scholar
• RussellRDeterminants of structure-function relationships among bisphosphonatesBone2007405S21S25
   Web of Science ®Google Scholar
• ShobackDUpdate in osteoporosis and metabolic bone disordersJ Clin Endocrinol Metab200792374775317341572
   PubMed Web of Science ®Google Scholar
• BoonenSVanderschuerenDVenkenKMilisenKDelforgeMHaentjensPRecent developments in the management of postmeno-pausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced complianceJ Intern Med2008264431533218823505
   PubMed Web of Science ®Google Scholar
• BlackDDelmasPEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• LylesKColon-EmericCMagazinerJZoledronic acid and clinical features and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• DunfordJThompsonKFPFCStructure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
   PubMed Web of Science ®Google Scholar
• RodanGFleischHBisphosphonates: mechanism of actionsJ Clin Invest199697269226968675678
   PubMed Web of Science ®Google Scholar
• LehenkariPKellinsalmiMNäpänkangasJFurther insight into mechanism of action of clodronate:inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenosine containing metaboliteMol Pharmacol20026151255126211961144
   PubMed Web of Science ®Google Scholar
• FrithJMonkkonenJAuriolaSMönkkönenHRogersMThe molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosisArthritis Rheum20014492201221011592386
   PubMed Web of Science ®Google Scholar
• RussellRBisphosphonates: from bench to bedsideAnn N Y Acad Sci2006106836740116831938
   PubMed Web of Science ®Google Scholar
• BergstromJBostedorRMasarachiaPReszkaARodanGAlendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthaseArch Biochem Biophys2000373123124110620343
   PubMed Web of Science ®Google Scholar
• LiEDavisLZoledronic acid: a new parenteral bisphosphonateClin Ther200325112669270814693298
   PubMed Web of Science ®Google Scholar
• GreenJChemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studiesSemin Oncol2001282 Suppl 641011346859
   PubMed Web of Science ®Google Scholar
• BenfordHMcGowanNHelfrichMNuttallMRogersMVisualization of bisphosphonateinduced caspase-3 activity in apoptotic osteoclasts in vitroBone200128546547311344045
   PubMed Web of Science ®Google Scholar
• BoissierSFerrerasMPeyruchaudOBisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastasesCancer Res200060112949295410850442
   PubMed Web of Science ®Google Scholar
• NancollasGTangRGuideSMineral binding affinities and zeta potentials of bisphosphonatesJ Bone Miner Res200217 Suppl 1S368
   Google Scholar
• NancollasGTangRPhippsRNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyappetiteBone200638561762716046206
   PubMed Web of Science ®Google Scholar
• HornbySEvansGHornbySPatakiAGlattMGreenJLong-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult ratsCalcif Tissue Int200372451952712574877
   PubMed Web of Science ®Google Scholar
• BinkleyNKimmelDBrunerJZoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeysJ Bone Miner Res19981311177517829797488
   PubMed Web of Science ®Google Scholar
• Novartis, Reclast (zoledronic acid)East Hanover, NJ 82007
   Google Scholar
• GreenJMullerKJaeggiKPreclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compoundJ Bone Miner Res1994597457518053405
   PubMed Web of Science ®Google Scholar
• ChenTBerensonJVescioRPharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastasesJ Clin Pharmacol200242111228123612412821
   PubMed Web of Science ®Google Scholar
• BoonenSSellmeyerDLippunerKRenal safety of annual zoledronic acid infusions in osteoporotic postmenopausal womenKidney Int20087464164818509324
   PubMed Web of Science ®Google Scholar
• McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone200741112212817468062
   PubMed Web of Science ®Google Scholar
• ReidIBrownJBurckhardtPIntravenous Zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med2002346965366111870242
   PubMed Web of Science ®Google Scholar
• PatrickMPurcellWBBoydIWBisphosphonates and osteonecrosis of the jawMJA2005182841741815850440
   PubMed Web of Science ®Google Scholar
• VieillardMMaesJPenelGThirteen cases of jaw osteonecrosis in patients on bisphosphonate therapyJoint, Bone, Spine: Revue du Rhumatisme20087513440
   Web of Science ®Google Scholar
• BrooksJGilsonASindlerAAshmanSSchwartzKNikitakisNOsteonecrosis of the jaws associated with use of risedronate: report of 2 new casesOral Surg Oral Med Oral Pathol Oral Radiol Endod2007103678078617223592
   PubMed Web of Science ®Google Scholar
• MashibaTMoriSBurrDThe effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog ribJ Bone Miner Metab200523 SupplS36S42
   Web of Science ®Google Scholar
• KomatsubaraSMoriSMashibaTLong term treatment of incdronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebraJ Bone Miner Res20031851252012619936
   PubMed Web of Science ®Google Scholar
• AllenMIwataKPhippsRothers aResidroante and alendroante similarly suppress remodeling and increase microdamage in beagles after 1 year of treatment at clinical doses27th Annual Meeting of the American Society for Bone and Mineral ResearchNashville, Tennessee, USAJ Bone Miner Res2005S22
   Google Scholar
• ReckerREnsrudKDiemSNormal Bone Histomorphometry and 3D microarchitecture after 10 years alendronate treatment of post-menopausal women26th Annual meeting of the American Society for Bone and Mineral ResearchSeattle, Washington, USA2004S45
   Google Scholar
• SaagKLindsayRKriegmanABeamerEZhouWA single zole-dronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBone20074051238124317347063
   PubMed Web of Science ®Google Scholar
• BorbaVPaz-FilhoGBone turnover 18 months after a single intravenous dose of zoledronic acidInt J Clin Pract20076161058106217504370
   PubMed Web of Science ®Google Scholar
• DevogelaerJBrownJBurkhardtPZoledronic acid efficacy and safety over five years in postmenopausal osteoporosisOsteoporos Int20071891211121817516022
   PubMed Web of Science ®Google Scholar
• BruyereOBrandiMBurletNPost-fracture management of patients with hip fracture: a perspectiveCurr Med Res Opin200824102841285118759997
   PubMed Web of Science ®Google Scholar
• DuqueGIntravenous zoledronic acid reduced new clinical fractures and deaths in patients who had recent surgery for hip fractureACP J Club200814824018311870
   PubMedGoogle Scholar
• BlackDCummingsSKarpfDRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• CranneyAWaldeggerLZytarukNRisedronate for the prevention and treatment of postmenopausal osteoporosisCochrane Database Syst Rev20034CD00452314584020
   PubMedGoogle Scholar
• DuqueGDemontieroOTroenBThe prevention and treatment of senile osteoporosis and hip fracturesMinerva Medica (in press)
   Google Scholar
• SilvermanSAdherence to medications for the treatment of osteoporosisRheum Dis Clin North Am200632472173117288974
   PubMed Web of Science ®Google Scholar
• YoodREmaniSReedJLewisBCharpentierMLydickECompliance with pharmacologic therapy for osteoporosisOsteoporos Int2003141296596814504697
   PubMed Web of Science ®Google Scholar
• SirisEHarrisSRosenCAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• Colón-EmericCLylesKLevineDPrevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fractureOsteoporos Int200718455355917120179
   PubMed Web of Science ®Google Scholar
• WellsGCranneyAPetersonJAlendronate for the primary and secondary prevention of osteoporotic fractures in postmeno-pausal womenCochrane Database Syst Rev20081Art. No.: CD001155
   Web of Science ®Google Scholar
• WellsGCranneyAPetersonJRisedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenCochrane Database Syst Rev20081CD00452318254053
   PubMed Web of Science ®Google Scholar